Disease

Metastatic Lung Non Small Cell Carcinoma

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 13, 2026 · PHASE 1 TRIAL

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

ClinicalTrials.gov

Phase 1b dose-escalation trial with no results reported; this is a registry record describing a planned study design, not outcome data.

PreliminaryStage IVA Lung Cancer AJCC V8 Stage Iv Lung Cancer AJCC V8 Multigated Acquisition Scan

Reported

Planned enrollment24

Study phasePhase 1b

Primary outcome measureMaximum tolerated dose, up to 28 days

AUG 12, 2026 · PHASE 2 TRIAL

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

ClinicalTrials.gov

This is a Phase 2 trial registry record with only 5 enrolled participants and no results posted; it represents early-phase work that requires confirmation.

PreliminaryStage Iv Lung Cancer AJCC V8 Computed Tomography National Cancer Institute (NCI)

Reported

Sample size5

PhasePhase 2

Primary endpointProgression Free Survival from start of tre…

AUG 12, 2026 · PHASE 1 TRIAL

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

ClinicalTrials.gov

This is a Phase 1 safety and feasibility study of a novel PET imaging agent in a small planned cohort with no results yet reported in the registry record.

PreliminaryComputed Tomography Low Dose Radiation Therapy Metastatic Lung Non Small Cell Carcinoma

Reported

Planned enrollment6

Study phasePhase 1

Primary outcome measure 1Incidence of treatment-related adverse even…